A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder

Trial Profile

A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Trigriluzole (Primary)
  • Indications Obsessive-compulsive disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical
  • Most Recent Events

    • 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the dosing for this trial was commenced in December 2017.
    • 02 Jan 2018 Planned initiation date changed from 31 Dec 2017 to 19 Dec 2017.
    • 14 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top